scholarly journals Comparative analysis of dietary pattern, anthropometry and serum ascorbate status of persons living with or without non-Hodgkin’s lymphoma

2018 ◽  
Author(s):  
Abiodun Adeoso ◽  
Tola Atinmo
Keyword(s):  
Dietary Pattern ◽  
Hodgkin’S Lymphoma ◽  
Food Preferences ◽  
Hodgkin's Lymphoma ◽  
Control Group ◽  
Chi Square ◽  
College Hospital ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
The University

Recent upsurge of cancer cases across the globe is of concern to all and many studies shows the relationship between nutrient and the immune system and consequently cancer. This work aims to compare the dietary pattern, anthropometry and serum ascorbate status of the persons living with and those living without non-Hodgkin’s lymphoma (NHL). A case-control study was conducted using blood samples of eight patients diagnosed for NHL at the University College Hospital (UCH) Ibadan, while eight (8) volunteers were the control group. Socio-economic characteristics, medical history, food preferences, anthropometric indices were retrieved from questionnaires. Ascorbic Serum assay done with ultraviolet absorption spectrophotometry method using Klett-summerson photoelectric. Students’ t-test and Chi-square were used to test the educational levels fruit consumption. 25% of the respondents suffering from NHL skipped lunch and dinner, but none skipped breakfast. 66.67% of the cases and 100% of the control have their weight normally distributed. Cases had 11.11% slightly underweight and 11.11% obese. 25% of the population of the respondents had normal range of 0.4 mg/100 of serum ascorbate, while six had low serum ascorbate levels.

scholarly journals Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma

Blood ◽  
1996 ◽  
Vol 87 (7) ◽  
pp. 2675-2682 ◽  
Author(s):  
A Osterborg ◽  
MA Boogaerts ◽  
R Cimino ◽  
U Essers ◽  
J Holowiecki ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Regression Analysis ◽  
Recombinant Human Erythropoietin ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Fixed Dose ◽  
Control Group ◽  
Human Erythropoietin ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

One hundred twenty-one anemic, transfusion-dependent patients with multiple myeloma (MM) or low-grade non-Hodgkin's lymphoma (NHL) were randomly allocated to receive (a) recombinant human erythropoietin (rhEPO) 10,000 U/d subcutaneously 7 days a week (fixed dose group) (n = 38), or (b) rhEPO 2,000 U/d subcutaneously for 8 weeks followed by step- wise escalation of the rhEPO dose (titration group) (n = 44), or (c) no rhEPO therapy (control group) (n = 39). The total treatment period was 24 weeks. There were no differences between the three groups with regard to baseline clinical, demographic, or health status measures. The cumulative response frequency, defined as elimination of the transfusion need in combination with an increase in the hemoglobin concentration by >20 g/L, was 60% in both rhEPO treatment groups and 24% in the control group (P = .01 and .02, respectively, log rank test). For patients in the titration group the response rate on the first dose level (2,000 U/d) was only 14%. Cox's univariate regression analysis revealed that an inadequately low endogenous erythropoietin concentration in relation to the degree of anemia and a baseline platelet concentration > or = 100 x 10(9)/L were significant predictors for response to rhEPO therapy (P < .01). Multivariate regression analysis showed that relative erythropoietin concentration was the most important factor and the platelet count had no additional influence on response. Treatment with rhEPO was well tolerated. We conclude that treatment with rhEPO may be indicated in anemic MM and NHL patients with a relative erythropoietin deficiency. An initial dose of 5,000 U/d subcutaneously may be recommended.

scholarly journals Pattern of Immunophenotype Among the Cases of Lymphoma Attending in A Tertiary Level Hospital

2019 ◽  
Vol 17 (2) ◽  
pp. 21-25
Author(s):  
Shirajam Munira ◽  
Salama Afroze ◽  
Akhil Ranjon Biswas ◽  
MA Khan
Keyword(s):  
T Cell ◽  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Hodgkin's Lymphoma ◽  
College Hospital ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Background : To explore the relative frequency and different forms of lymphoma in tertiary level hospital. Methods: This descriptive observational study was carried out in the Department of Hematology at Dhaka Medical College Hospital, Dhaka. Patients attended with solid tissue lymphoma in Outpatient, Inpatient and Lymphoma Clinic services of Department of Hematology and Bone Marrow Transplant, Dhaka Medical College Hospital, Dhaka were taken as study population as per inclusion criteria. A total of 63 patients with lymphoma diagnosed by histopathologically were selected initially, among them 53 were confirmed by immunohistochemistry taken as study population finally. Results: Mean age was 39.2 ± 15.5 years, median age was 36 years within the range of 14 – 75 years. Males were predominant. Male female ratio was 4.3:1. Most of the samples were collected from cervical lymph node (84.1%). Most of the patients came with fatigue and significant weight loss. Maximum 42 (79.24%) cases were Non-Hodgkin’s lymphoma and 11 (20.75%) cases were Hodgkin’s lymphoma. Out of 42 non-Hodgkin’s lymphoma, 27 (64.3%) were B-cell lymphoma and 15 (35.7%) were T-cell lymphoma. Among B-cell lymphoma, 19 (45.2%) were diffuse large B cell lymphoma, three (7.1%) were follicular lymphoma, three (7.1%) were mantle cell lymphoma, one (2.4%) was spleenic marginal zone lymphoma and one (2.4%) was Burkitt lymphoma. Among T-cell lymphoma, nine (21.4%) were peripheral T-cell lymphoma and six (14.3%) were adult T lymphoblastic lymphoma. Out of 11 Hodgkin’s lymphoma, 10 (90.9%) were classical Hodgkin’s lymphoma and one (9.1%) nodular lymphocyte predominant. Among classical Hodgkin’s lymphoma, five (45.5%) were mixed cellularity, three (27.3%) were lymphocyte predominant and two (18.2%) were Nodular sclerosis. Out of 42 non-Hodgkin’s lymphoma, 13 (30.95%) were indolent, 21 (50.00%) were aggressive and eight (19.05%) were very aggressive. Conclusion: In our study, it was found that 79.3% were non-Hodgkin lymphoma of which 64.3% were B-cell lymphoma & 35.7% were T-cell lymphoma and 20.7% cases were Hodgkin lymphoma of which 90.9% were classical Hodgkin’s lymphoma, 9.1% nodular lymphocyte predominant Hodgkin’s lymphoma. Chatt Maa Shi Hosp Med Coll J; Vol.17 (2); Jul 2018; Page 21-25

scholarly journals Are blood donors an adequate control group to ascertain HCV prevalence in non-Hodgkin's lymphoma patients

2002 ◽  
Vol 17 (9) ◽  
pp. 1039-1040 ◽  
Author(s):  
Emilio Iannitto ◽  
Stefano De Cantis ◽  
Sonia Cirrincione ◽  
Emanuele Ammatuna ◽  
Rosa Di Trapani ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Blood Donors ◽  
Hodgkin's Lymphoma ◽  
Control Group ◽  
Adequate Control ◽  
Non Hodgkin’S Lymphoma ◽  
Hcv Prevalence ◽  
Non Hodgkin's Lymphoma

Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

2002 ◽  
Vol 20 (10) ◽  
pp. 2453-2463 ◽  
Author(s):  
Thomas E. Witzig ◽  
Leo I. Gordon ◽  
Fernando Cabanillas ◽  
Myron S. Czuczman ◽  
Christos Emmanouilides ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Group Versus ◽  
Hodgkin's Lymphoma ◽  
Phase Iii ◽  
Control Group ◽  
Low Grade ◽  
Ibritumomab Tiuxetan ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Yttrium 90

PURPOSE: Radioimmunotherapy combines biologic and radiolytic mechanisms to target and destroy tumor cells, thus offering a needed therapeutic alternative for refractory non-Hodgkin’s lymphoma (NHL) patients. This phase III randomized study compares the novel radioimmunotherapy yttrium-90 (90Y) ibritumomab tiuxetan with a control immunotherapy, rituximab, in 143 patients with relapsed or refractory low-grade, follicular, or transformed CD20+ transformed NHL. PATIENTS AND METHODS: Patients received either a single intravenous (IV) dose of 90Y ibritumomab tiuxetan 0.4 mCi/kg (n = 73) or rituximab 375 mg/m2 IV weekly for four doses (n = 70). The radioimmunotherapy group was pretreated with two rituximab doses (250 mg/m2) to improve biodistribution and one dose of indium-111 ibritumomab tiuxetan for imaging and dosimetry. The primary end point, overall response rate (ORR), was assessed by an independent, blinded, lymphoma expert panel. RESULTS: ORR was 80% for the 90Y ibritumomab tiuxetan group versus 56% for the rituximab group (P = .002). Complete response (CR) rates were 30% and 16% in the 90Y ibritumomab tiuxetan and rituximab groups, respectively (P = .04). An additional 4% achieved an unconfirmed CR in each group. Kaplan-Meier estimated median duration of response was 14.2 months in the 90Y ibritumomab tiuxetan group versus 12.1 months in the control group (P = .6), and time to progression was 11.2 versus 10.1 months (P = .173) in all patients. Durable responses of ≥ 6 months were 64% versus 47% (P = .030). Reversible myelosuppression was the primary toxicity noted with 90Y ibritumomab tiuxetan. CONCLUSION: Radioimmunotherapy with 90Y ibritumomab tiuxetan is well tolerated and produces statistically and clinically significant higher ORR and CR compared with rituximab alone.

Antiphospholipid Antibodies: Prevalence, Clinical Significance and Correlation to Cytokine Levels in Acute Myeloid Leukemia and Non-Hodgkin’s Lymphoma

1993 ◽  
Vol 70 (04) ◽  
pp. 568-572 ◽  
Author(s):  
Roberto Stasi ◽  
Elisa Stipa ◽  
Mario Masi ◽  
Felicia Oliva ◽  
Alessandro Sciarra ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Clinical Significance ◽  
Antiphospholipid Antibodies ◽  
Myeloid Leukemia ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Tnf Alpha ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Acute Myeloid

SummaryThis study was designed to explore the prevalence and clinical significance of elevated antiphospholipid antibodies (APA) titres in patients affected by acute myeloid leukemia (AML) and highgrade non-Hodgkin’s lymphoma (NHL). We also analyzed possible correlations with circulating levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and the soluble form of the receptor for interleukin-2 (sIL-2r). Nineteen patients with de novo AML and 14 patients with newly-diagnosed NHL were investigated. Tests for APA included the measurement of anticardiolipin antibodies (ACA) with a solid-phase immunoassay, and the detection of the lupus-like anticoagulant (LA) activity. Five patients with AML (26.3%) and 5 patients with NHL (35.7%) presented elevated APA at diagnosis, as compared to 3 of 174 persons of the control group (p <0.0001). APA titres became normal in all patients responding to treatment, whereas nonresponders retained elevated levels. In addition, 6 patients (4 with AML and 2 with NHL), who had normal APA at diagnosis and were either refractory to treatment or in relapse, subsequently developed LA and/or ACA positivity. At presentation, the mean levels of IgG- and IgM-ACA in patients were not significantly different from Controls, and concordance between ACA and LA results reached just 30%. With regard to the clinical course, we were not able to detect any statistically significant difference between patients with normal and elevated APA. Pretreatment concentrations of IL-6 and TNF-alpha in AML, and sIL-2r in NHL were found significantly elevated compared to Controls (p = 0.003, p = 0.009 and p = 0.024 respectively). In addition, the levels of these cytokines correlated with IgG-ACA at the different times of laboratory investigations. These results demonstrate that APA may have a role as markers of disease activity and progression in some haematological malignancies.

Sign in / Sign up

Export Citation Format

Share Document